Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01055262
First received: January 21, 2010
Last updated: May 7, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | January 21, 2010 | ||||
| Last Updated Date | May 7, 2012 | ||||
| Start Date ICMJE | January 2010 | ||||
| Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Percentage of Participants With a Significant Skin Event (Day 5 Cumulative) [ Time Frame: Day 2 to Day 6 ] [ Designated as safety issue: Yes ] Events associated with Day X wear (eg, Day 5) assessed morning of Day X+1 (eg, Day 6). Significant skin event: at least moderate erythema, elevated response or pain upon touch (associated with non-zero erythema). Erythema grading scale: 0 (no visible erythema) to 3.0 (severe erythema, very intense redness) with 0.5 increments. Moderate erythema (2.0): definite redness. Elevated response: edema, papules, vesicle (≤ 0.5 centimeter [cm] diameter), bullae (> 0.5 cm diameter), miliaria rubra, profunda or follicular response. Pain upon touch: skin grader asked "Does your skin hurt when I touch it?" |
||||
| Original Primary Outcome Measures ICMJE |
Day 5 cumulative percentage of subjects with a significant skin event, defined as at least moderate eyrthema on erythema grading scale, an elevated response, or pain upon touch (associated with non-zero erythema) based on morning skin grading. [ Time Frame: 5 days ] [ Designated as safety issue: Yes ] | ||||
| Change History | Complete list of historical versions of study NCT01055262 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE |
Time to first report of at least moderate erythema on erythema grading scale, an elevated response, or pain upon touch (associated with non-zero erythema) based on morning skin grading; maximum on-body skin temperature over 8 hours [ Time Frame: 5 days ] [ Designated as safety issue: Yes ] | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back | ||||
| Official Title ICMJE | An Open Label Study To Evaluate The Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back | ||||
| Brief Summary | The objectives of this study are to evaluate the dermal safety and on-body temperature of a disposable heatwrap product when worn while in a supine position for five consecutive days. The product will be worn on the back for approximately 8 hours per 24 hour period. |
||||
| Detailed Description | Purpose-To obtain safety , tolerability and on-body temperature of a heatwrap device for the lower back. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Phase 3 | ||||
| Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label |
||||
| Condition ICMJE | Healthy | ||||
| Intervention ICMJE | Device: Heatwrap 1
8 hours continuous topically-applied heat |
||||
| Study Arm (s) | Experimental: Heatwrap 1
Experimental heatwrap device for the lower back
Intervention: Device: Heatwrap 1 |
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 169 | ||||
| Completion Date | February 2010 | ||||
| Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 35 Years and older | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | Not Provided | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT01055262 | ||||
| Other Study ID Numbers ICMJE | TC-09-06, TC-09-06 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Pfizer | ||||
| Study Sponsor ICMJE | Pfizer | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Pfizer | ||||
| Verification Date | May 2012 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||